title: Field Treatment of Actinic Keratosis With Ingenol Mebutate.
abstract: There is a need for early, effective field treatments for actinic keratosis (AK) that target subclinical as well as clinically visible lesions to minimize the recurrence and emergence of new lesions. Ingenol mebutate gel is an effective and well-tolerated topical field therapy that has demonstrated sustained clearance and long-term reduction of AKs. This article reviews findings from the FIELD study program and highlights health-related quality of life (HRQoL) outcomes for patients receiving ingenol mebutate. Efficacy data from the FIELD study program are discussed and the tolerability profile of ingenol mebutate in the treatment of areas of up to 100 cm2 is considered. These findings are then placed in the context of HRQoL outcomes and their relevance for patients.<br /><br /> <em>J Drugs Dermatol</em>. 2016;15(5):535-542.
authors.forename: Brian
authors.initials: B
authors.lastname: Berman
authors.forename: Eggert
authors.initials: E
authors.lastname: Stockfleth
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D004224:Diterpenes / Q000008:administration & dosage*; D006801:Humans; D055623:Keratosis, Actinic / Q000175:diagnosis* / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life / Q000523:psychology; D016896:Treatment Outcome
chemical_list: C486592:3-ingenyl angelate; D004224:Diterpenes